Regulators and lawmakers have expressed concern over possible privacy breaches as Google and Ascension collect healthcare data; Amarin’s Vascepa goes before an FDA committee this week; CMS Administrator Seema Verma defends Medicaid work requirements.
Regulators and lawmakers have expressed concern over possible privacy breaches, according to The Wall Street Journal, as Google works with Ascension to collect health information on 50 million American patients. They are calling for both additional government oversight and a temporary halt to the program. Meanwhile, Google and Ascension claim the data collection is meant to improve healthcare, and a Google spokeswoman says nothing the company gathers will be used to sell ads.
With potential sales of $3.2 billion by 2030 on the line, an FDA report gave a largely positive review to Amarin’s Vascepa ahead of its advisory committee meeting Thursday. However, as Amarin tries to expand the label for its fish oil—derived drug—first approved for use in the United States in 2012 to lower high triglyceride levels—to include that it reduces heart attacks and strokes in patients with cardiovascular disease, some experts claim trial results are skewed, Reuters reported. They believe that using mineral oil as the drug trial’s placebo worsened cholesterol levels in patients or affected the absorption of the statins they were on, tilting results in Vascepa’s favor.
On the same day CMS Administrator Seema Verma sharply defended the administration’s controversial work requirement rules forcing some Medicaid beneficiaries to work—a policy that led to thousands losing health insurance in Arkansas—the department also announced it would tighten the so-called supplemental payments to states for extra Medicaid funding for hospitals, nursing homes, and doctors. The US government spent about $48.5 billion on these payments in 2016, Kaiser Health News reported. Speaking before the National Association of Medicaid Directors in Washington, DC, Verma said that states and providers must be more transparent in how they spend the funds.
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More